Render Target: SSR
Render Timestamp: 2025-01-16T19:32:32.569Z
Commit: da7e4f2f0d1aed1f1f8e20e4e2ecab8f33cbd595
XML generation date: 2024-04-05 20:18:24.809
Product last modified at: 2025-01-01T09:04:43.765Z
Cell Signaling Technology Logo
1% for the planet logo
PDP - Template Name: Antibody Sampler Kit
PDP - Template ID: *******4a3ef3a

JARID1/KDM5 Histone Demethylase Antibody Sampler Kit #25497

    Product Information

    Product Description

    The JARID1/KDM5 Histone Demethylase Antibody Sampler Kit provides an economical means for detecting the JARID1/KDM5 family of proteins. The kit includes enough antibodies to perform two western blot experiments with each primary antibody.

    Specificity / Sensitivity

    Each antibody in the JARID1/KDM5 Histone Demethylase Antibody Sampler Kit detects endogenous levels of its target protein. JARID1A (D28B10) Rabbit mAb detects endogenous levels of both isoforms of total JARID1A protein.

    Source / Purification

    Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Ala274 of human JARID1A protein and Leu830 of human JARID1C protein, near the amino terminus of human JARID1B protein, and near the carboxy terminus of human JARID1D protein.

    Background

    The methylation state of lysine residues in histone proteins is a major determinant for formation of active and inactive regions of the genome and is crucial for proper programming of the genome during development (1,2). Jumonji C (JmjC) domain-containing proteins represent the largest class of potential histone demethylase proteins (3). The JmjC domain can catalyze the demethylation of mono-, di-, and tri-methyl lysine residues via an oxidative reaction that requires iron and α-ketoglutarate (3). Based on homology, both humans and mice contain at least 30 such proteins, which can be divided into 7 separate families (3). The JARID (Jumonji/AT-rich interactive domain-containing protein) family contains four members: JARID1A (also RBP2 and RBBP2), JARID1B (also PLU-1), JARID1C (also SMCX), and JARID1D (also SMCY) (4). In addition to the JmJC domain, these proteins contain JmJN, BRIGHT, C5HC2 zinc-finger, and PHD domains, the latter of which binds to methylated histone H3 (Lys9) (4). All four JARID proteins demethylate di- and tri-methyl histone H3 Lys4; JARID1B also demethylates mono-methyl histone H3 Lys4 (5-7). JARID1A is a critical RB-interacting protein and is required for Polycomb-Repressive Complex 2 (PRC2)-mediated transcriptional repression during ES cell differentiation (8). A JARID1A-NUP98 gene fusion is associated with myeloid leukemia (9). JARID1B, which interacts with many proteins including c-Myc and HDAC4, may play a role in cell fate decisions by blocking terminal differentiation (10-12). JARID1B is overexpressed in many breast cancers and may act by repressing multiple tumor suppressor genes, including BRCA1 and HOXA5 (13,14). JARID1C has been found in a complex with HDAC1, HDAC2, G9a, and REST, which binds to and represses REST target genes in non-neuronal cells (7). JARID1C mutations are associated with X-linked mental retardation and epilepsy (15,16). JARID1D is uniquely localized to the Y chromosome, and functions as a tumor suppressor by repressing genes associated with cell invasiveness (17). JARID1D is frequently mutated in metastatic prostate tumors, and low JARID1D levels are associated with poor prognosis in prostate cancer patients (17).
    1. Kubicek, S. et al. (2006) Ernst Schering Res Found Workshop, 1-27.
    2. Lin, W. and Dent, S.Y. (2006) Curr Opin Genet Dev 16, 137-42.
    3. Klose, R.J. et al. (2006) Nat Rev Genet 7, 715-27.
    4. Benevolenskaya, E.V. (2007) Biochem Cell Biol 85, 435-43.
    5. Christensen, J. et al. (2007) Cell 128, 1063-76.
    6. Yamane, K. et al. (2007) Mol Cell 25, 801-12.
    7. Tahiliani, M. et al. (2007) Nature 447, 601-5.
    8. Pasini, D. et al. (2008) Genes Dev 22, 1345-55.
    9. van Zutven, L.J. et al. (2006) Genes Chromosomes Cancer 45, 437-46.
    10. Secombe, J. et al. (2007) Genes Dev 21, 537-51.
    11. Barrett, A. et al. (2007) Int J Cancer 121, 265-75.
    12. Dey, B.K. et al. (2008) Mol Cell Biol 28, 5312-27.
    13. Barrett, A. et al. (2002) Int J Cancer 101, 581-8.
    14. Lu, P.J. et al. (1999) J Biol Chem 274, 15633-45.
    15. Tzschach, A. et al. (2006) Hum Mutat 27, 389.
    16. Jensen, L.R. et al. (2005) Am J Hum Genet 76, 227-36.
    17. Li, N. et al. (2016) Cancer Res 76, 831-43.
    For Research Use Only. Not For Use In Diagnostic Procedures.
    Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
    All other trademarks are the property of their respective owners. Visit our Trademark Information page.